clinical trial · NCT05892757
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
AbbVie·phase1·completed·n = 24
Healthy VolunteersAtogepantUbrogepant
brief summary
This study will assess adverse events and compare how ubrogepant and atogepant tablets move through the body of healthy adult lactating female participants. Ubrogepant and atogepant are approved drugs for treatment of migraine in adults. Participants will be assigned to one of the 2 treatment arms to receive atogepant or ubrogepant. Approximately 24 healthy adult lactating female participants will be enrolled at 3 sites in the United States Participants will receive oral tablets of ubrogepant or atogepant on Day 1 and will be followed for 30 days.
started
Jul 11, 2023
primary completion
Feb 22, 2024
completion
Feb 22, 2024
last updated
Mar 12, 2024
official title
A Phase 1 Lactation Study in Healthy Adult Lactating Female Subjects One to Six Months Post-Partum to Evaluate the Pharmacokinetics and Safety of Ubrogepant and Atogepant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol